1. |
Rotavirus vaccines: universal access soon? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
2. |
New rules to govern clinical trials in India? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
3. |
New paediatric influenza vaccination recommendations have been published by the US Centers for Disease Control and Prevention |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
4. |
News from the 16th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 5-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
5. |
Triptan use in France not currently ideal |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
6. |
One-dose immunisation best for meningococcal group C infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
7. |
The investigational polymer therapy, tolevamer*, shows promise in the treatment ofClostridium difficile-associated diarrhoea, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
8. |
Daclizumab improves control of chronic persistent asthma |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 9-10
Innes Carmen,
Preview
|
|
摘要:
The humanised monoclonal antibody daclizumab is effective in patients with chronic, persistent asthma whose disease is not well controlled with high doses of inhaled corticosteroids, according to results of a phase II study presented at the 60thAnnual Meeting of the American Academy of Allergy, Asthma and Immunology [San Francisco, US; March 2004]. Results at 12 weeks showed that patients treated with daclizumab had significantly improved FEV1values, the primary study endpoint, compared with patients who received placebo. In addition, daclizumab significantly prolonged the time to systemic corticosteroid rescue and reduced eosinophil counts, relative to placebo.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
9. |
Intravesical administration of bio-adhesive paclitaxel microspheres appears promising in bladder cancer, |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
10. |
BB 83698 active against streptococci andMoraxella catarrhalis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1437,
2004,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|